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The HUPO Plasma Proteome Project new phase, PPP-2, held its initial workshop on 17 August,
2008, at the 7th World Congress of Proteomics in Amsterdam. Technology platforms, data repo-
sitories, informatics, and engagement of research groups for the submission of major datasets
were key topics. Plasma is expected to be the common pathway for biomarker development and
application through collaboration and integration with other HUPO initiatives.
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At the 7th World Congress of Proteomics in Amsterdam,
17th August 2008, the HUPO Plasma Proteome Project new
phase, PPP-2, held its annual Workshop. The aims of the PPP-2
are (i) to stimulate submission of high-quality, large datasets of
human plasma proteome findings with advanced technology
platforms; (ii) to establish a robust, value-added informatics
scheme involving EBI/PRIDE [1], University of Michigan/
ProteomeCommons/Tranche, and Institute for Systems Biol-
ogy/Peptide Atlas [2]; and (iii) to collaborate with other HUPO
organ-based and disease-related initiatives to make plasma the
common pathway for biomarker development and application.
After an introduction from Gil Omenn about the output
from PPP-1 [3] and aims of PPP-2 [4], Ruedi Aebersold laid
out a new strategy for plasma studies, emphasizing resolu-
tion and quantification deeper into the dynamic range of
protein concentrations (,1 ng/ml), targeted analyses of
high-interest proteins, and cooperative sharing of high-con-
tent data. He described selective or multiple reaction mon-
itoring (SRM/MRM) of peptide ion transitions as a “mass
spectrometry equivalent of multiplex ELISA” and noted the
TIQAM MRM software and the PeptideAtlas from ISB as
aids in designing these analyses.
The first datasets to be submitted under the PPP-2 Pro-
teomExchange scheme developed by Lennart Martens and
Eric Deutsch (www.hupo.org/PPP-2) were uploaded at
PRIDE in time to be demonstrated real-time during the
Workshop. This scheme provides the community the origi-
nal highly annotated dataset and investigator’s analyses at
PRIDE [5]; distributed, secure file sharing by Tranche
(www.tranche.proteomecommons.org); and automatic
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transfer to PeptideAtlas [6], where the raw spectra are uni-
formly re-analyzed with the TransProteomicPipeline to gen-
erate consolidated data on the plasma peptidome and pro-
teome for comparative studies. Both PRIDE and Pepti-
deAtlas are creating readily identified web pages for the PPP-
2. The entire scheme is outlined in Figure 1.
Jon Jacobs of Richard Smith’s group at Pacific NW Labo-
ratory described three large datasets that were submitted: (i)
303 human N-glycoproteins, based on 63 runs on LCQ and
LTQ instruments after treatment of a single normal EDTA-
plasma specimen with hydrazide, trypsin, and PNGase [7];
(ii) the plasma proteome from trauma patients from the
Inflammation and Host Response to Injury Program, iden-
tifying 1494 multi-peptide proteins and 662 N-glycoproteins
with Mixed-12 partition and 120 runs on LTQ [8]; and (ii) a
normal human EDTA-plasma proteome after Mixed-12 and
Supermix depletion of 99 percent of protein mass, yielding
695 multi-peptide proteins [9]. The entire uploading process
and release for public access at PRIDE was completed within
a week.
Parag Mallick at the Spielberg Family Center for
Applied Proteomics at Cedars Sinai Medical Center in Los
Angeles, California, provided a terabyte of raw files, XML
files, and related annotation of 32 experiments exploring
reproducibility, sensitivity, fractionation, dynamic exclu-
sion, selective inclusion, and gradient retention time
warping. The sample is a pool from 20 healthy males,
called “Bucket of Blood” (BOB). The PRIDE and Tranche
steps performed smoothly. Over 5000 proteins were identi-
fied. These data had not yet been submitted for publication
at the time of the Workshop. Mallick made several sug-
gestions for enhancements of the quality assurance, meta-
data and software for parsing.
The third aim of the PPP-2 was addressed by leaders of
other HUPO initiatives. Laura Beretta of the Fred Hutchin-
Figure 1. The ProteomExchange scheme shows the roles of
investigators as data producers, the successive roles of PRIDE,
Tranche, and PeptideAtlas, and the opportunity for researchers
globally to utilize the original and the re-analyzed datasets from
the Plasma Proteome Project (PPP-2) to explore and test their
own queries. The links with other proteome studies will be par-
ticularly important.
son Cancer Research Center, current chair of the Human
Liver Proteome Project (HLPP), described the comparative
analysis of liver and plasma proteomes and their changes
with disease progression in two mouse models of hepatocel-
lular carcinoma. She advocated future studies aimed at better
understanding how proteome changes in diseased tissue
translate into proteome changes in plasma and called for
collaborative projects between HLPP and PPP. Numerous
comparative studies will be desirable.
Jong Shih Yoo of the Korean Basic Science Institute
described a label-free method for quantitation of pooled
plasma proteins and N-glycosite peptides from normals
and hepatocellular carcinoma (HCC) patients. Tadashi
Yamomoto of Niigata University in Japan, chair of the Hu-
man Kidney-Urine Proteome Project, reported results
available at www.hupo.org and at PRIDE for urine and for
dissected glomeruli, with over 3000 proteins identified. The
urine, of course, is a filtrate of plasma, altered by proteins
released or secreted from the glomerular and tubular
compartments of the kidney. On behalf of Weihong Yan,
David Wong, and Joseph Loo at UCLA, Omenn briefly
summarized results on the human salivary proteome, both
whole saliva and separate parotid gland and sub-
mandibular/sublingual gland fractions [10]. Young-Ki Paik
of Yonsei Proteome Research Center in Korea introduced
BiomarkerDigger, which combines multiple databases with
analytical functions which automate data analysis, search-
ing, and metadata-gathering functions. BiomarkerDigger
can highlight relationships between a given protein in a
proteomic dataset and known biomarkers or biomarker
candidates as illustrated for hepatocellular carcinoma. Bio-
markerDigger was designed for use in the HUPO Plasma
Proteome Project pilot phase and is being used routinely
by the Paik lab for analyzing protein–protein interactions,
protein networks, and functional expression information of
the human plasma proteome. Finally, Omenn referred to
Michigan Molecular Interactions (MiMI) (https://portal.
ncibi.org/MiMI) [11]; and its Cytoscape plug-in [12] for
convenient annotation of protein–protein interactions and
visualization of networks.
Investigators are invited to submit major datasets to PPP-
2, with raw spectra and full annotation. Notify Lennart Mar-
tens (lennart.martens@ebi.ac.uk) and Gil Omenn of your
intentions. Readers are encouraged to nominate studies by
others that the HUPO PPP-2 co-chairs should request. We
hope many researchers will make use of these resources at
PRIDE, Tranche, and PeptideAtlas to address their own bio-
logical and clinical questions.
We warmly acknowledge the productive collaboration of the
many HUPO PPP contributors, laboratory investigators and
analysts, our technical committees, 7th HUPO World Congress
sponsors and vendors, as well as the HUPO leadership.
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